HPGD and cancer: Our recent research showed that NAD+ decline promoted epithelial-mesenchymal transition (EMT), migration, and invasion of cancer cells by activating the STAT3 signaling pathway and oxidatively degrading 15-hydroxyprostaglandin dehydrogenase (15-PGDH, an NAD+-dependent enzyme) via accumulated ROS.